WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Deutsche Bank 40th Annual Health Care Conference on May 6, 2015 at 4:10 p.m. EDT at the InterContinental Hotel, Boston, Mass.
The Company's presentation will be webcast live on the Company's website at www.radiuspharm.com, and a replay of the presentation will be available on the Company's website following the presentation. The Company will post a copy of the presentation materials on its website, www.radiuspharm.com, prior to the start of the presentation.
About Radius Health
Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. The company's lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com.